Quick Links

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


PER Pulse™ Recaps
for the Renal Cell Carcinoma: Recent Advances and New Questions symposium focus on current treatment algorithms, new agents, and management of adverse events in patients with renal cell carcinoma that were discussed by the expert faculty at this program.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Exelixis.

Renal Cell Carcinoma: Recent Advances, New Questions

Release Date: March 31, 2016
Expiration Date: March 31, 2017
Media: Internet - based

Activity Overview

This activity focuses on the field of renal cell carcinoma (RCC) management, and features a series of short video interviews with leading experts in the treatment of renal cell carcinoma. The content and interviews are based on presentations given at Renal Cell Carcinoma: Recent Advances and New Questions, a CME-certified, ancillary satellite symposium held in San Francisco, California.

CME Activity Table of Contents

  • First-Line Therapy in Metastatic Clear-Cell Renal Cell Carcinoma
  • Second-Line Therapy Following an Anti-Angiogenic Agent
  • Third-Line Therapy Following an Anti-Angiogenic Agent and Immunotherapy

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is intended for medical oncologists, surgical oncologists, radiation oncologists, urologists, and other healthcare professionals interested in the treatment of renal cell carcinoma.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:
  • Explain contemporary treatment strategies and unmet clinical needs in the setting of advanced RCC.
  • Describe emerging mechanistic approaches to overcome anti-angiogenic resistant RCC.
  • Delineate proactive measures to manage and mitigate predictable treatment-related side effects in patients who are managed for advanced forms of RCC in multiple lines of care.
  • Explain key clinical trial results to manage advanced RCC that has progressed despite frontline treatment approaches and ongoing trials that may inform clinical decision making on sequencing of therapies for patients with these tumors.

Faculty, Staff, and Planners' Disclosures


Toni Choueiri, MD
Clinical Director, Lank Center for Genitourinary Oncology
Director, Kidney Cancer Center
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, MA

Robert Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology-Oncology
Professor of Biomedical Sciences
Professor of Medicine
Director, Division of Hematology/Oncology
Cedars-Sinai Medical Center
Associate Director, Academic Program Development in the Samuel Oschin Comprehensive Cancer Institute
Los Angeles, CA

Hans Joerg Hammers, MD, PhD
Assistant Professor of Oncology, Johns Hopkins School of Medicine
Medical Oncologist, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Brian Rini, MD, FACP
Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Department of Solid Tumor Oncology, Cleveland Clinic
Cleveland, OH

The following individuals have no relevant financial relationships with commercial interests:

The staff of Physicians' Education Resource®, LLC

Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise


Become a Member

Forgot Password?
Filter By